Bausch Health Companies Inc. (BHC) is a publicly traded company in the Healthcare — Drug Manufacturers - Specialty & Generic industry listed on NYSE. This overview shows the latest price, key valuation ratios, profitability metrics and financial-health indicators used by fundamental investors.
Bausch Health Companies Inc., together with its associated entities, is engaged in the development, manufacturing, and commercialization of a diverse portfolio of pharmaceutical products, medical devices, and over-the-counter remedies. Its primary therapeutic focus areas include ophthalmology, digestive health, and dermatology.
Is Bausch Health Companies Inc. stock overvalued or undervalued in 2026?
As of October 29, 2026, Bausch Health Companies Inc. (BHC) trades at $8.91 with no positive earnings over the last twelve months, according to Kaplio. No valuation verdict: it has no earnings to calculate a P/E from.
Kaplio overview: Bausch Health Companies Inc.
Market cap $3B · 52 weeks $4 – $9 (0 % below the high) · P/E no earnings · 2027 expected P/E 2.0× · Dividend none · Next earnings February 17, 2027 · expected EPS $1.33 · Closing price, Oct 29 · accounts published Oct 28.
- Valuation: EV/EBITDA 0.5× (no earnings).
- Business: ROIC 63 % (fair).
- Balance sheet: Net debt/EBITDA 6.3× (fragile).
- Earnings: 3 of 8 (disappointing).
What would it be worth at its usual multiples?
No valuation verdict: it has no earnings to calculate a P/E from.
What matters in pharma: 3 of 5 pass
- R&D / Revenue 6.1 %, fails.
- Net debt / EBITDA 6.3×, fails.
- Gross margin 70.7 %, passes, near the threshold.
- FCF / Net Income 638.9 %, passes.
- ROIC 62.5 %, passes.
Against its peers (reference peers) — Bausch Health Companies Inc.: P/E —; EV/EBITDA 0.5×; ROIC 62.5 %; $3.3B. HUTCHMED (China) Limited (P/E 132×; EV/EBITDA —; ROIC -2.1 %; $2.4B), Catalyst Pharmaceuticals, Inc. (P/E 17.5×; EV/EBITDA 9.3×; ROIC 19.7 %; $3.9B), Concentra Group Holdings Parent, Inc. (P/E 25.9×; EV/EBITDA 15.8×; ROIC 10.5 %; $5.1B).
Profitability
| Return on Equity | 58.90% |
| Return on Invested Capital | 62.51% |
| Return on Assets | -3.30% |
| Gross Margin | 79.05% |
| Operating Margin | 28.04% |
| Net Margin | -7.59% |
Financial Health
| Debt / Equity | -0.65 |
| Current Ratio | 1.56 |
| Piotroski F-Score | 6 |
| Altman Z-Score | 0.30 |
Price Performance
| 1 month | +52.83% |
| 3 months | +29.32% |
| Year-to-date | +28.20% |
| 1 year | +34.80% |
| 3 years | +30.65% |
| 5 years | -68.27% |
| 10 years | -62.66% |
Dividend History
| Date | Amount |
|---|---|
| 2010-11-10 | $1.0000 |
| 2010-08-30 | $0.0950 |
| 2010-05-28 | $0.0950 |
| 2010-03-04 | $0.0900 |
| 2009-11-30 | $0.0900 |
| 2009-08-28 | $0.0900 |
| 2009-05-13 | $0.0900 |
| 2009-03-06 | $0.3750 |
| 2008-12-19 | $0.3750 |
| 2008-08-21 | $0.3750 |
Amounts adjusted for stock splits.
Related companies: BEAM · HCM · CON · HAE · PRGO
Explore sector: Healthcare · Drug Manufacturers - Specialty & Generic
More sections of BHC: Financials · Valuation · Statistics · Estimates · Technical · Ownership · News · Events
Discover more: Weekly Radar: the S&P 500 through the Buffett and Lynch methods · Companies that pass the Buffett method today · Companies that pass the Lynch method today · Stocks that pass Graham's defensive investor test today · Investment Academy — learn to analyze stocks